151 related articles for article (PubMed ID: 27107948)
1. Synthesis of a stable and orally bioavailable englerin analogue.
Fash DM; Peer CJ; Li Z; Talisman IJ; Hayavi S; Sulzmaier FJ; Ramos JW; Sourbier C; Neckers L; Figg WD; Beutler JA; Chain WJ
Bioorg Med Chem Lett; 2016 Jun; 26(11):2641-4. PubMed ID: 27107948
[TBL] [Abstract][Full Text] [Related]
2. Chemical synthesis of the englerins.
Pouwer RH; Richard JA; Tseng CC; Chen DY
Chem Asian J; 2012 Jan; 7(1):22-35. PubMed ID: 22162365
[TBL] [Abstract][Full Text] [Related]
3. Total synthesis and biological evaluation of (-)-englerin A and B: synthesis of analogues with improved activity profile.
Radtke L; Willot M; Sun H; Ziegler S; Sauerland S; Strohmann C; Fröhlich R; Habenberger P; Waldmann H; Christmann M
Angew Chem Int Ed Engl; 2011 Apr; 50(17):3998-4002. PubMed ID: 21472928
[No Abstract] [Full Text] [Related]
4. Englerin A, a selective inhibitor of renal cancer cell growth, from Phyllanthus engleri.
Ratnayake R; Covell D; Ransom TT; Gustafson KR; Beutler JA
Org Lett; 2009 Jan; 11(1):57-60. PubMed ID: 19061394
[TBL] [Abstract][Full Text] [Related]
5. Formal synthesis of (-)-englerin A and cytotoxicity studies of truncated englerins.
Xu J; Caro-Diaz EJ; Batova A; Sullivan SD; Theodorakis EA
Chem Asian J; 2012 May; 7(5):1052-60. PubMed ID: 22415793
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Biological Evaluation of New (-)-Englerin Analogues.
López-Suárez L; Riesgo L; Bravo F; Ransom TT; Beutler JA; Echavarren AM
ChemMedChem; 2016 May; 11(9):1003-7. PubMed ID: 27005578
[TBL] [Abstract][Full Text] [Related]
7. Total synthesis of englerin A.
Nicolaou KC; Kang Q; Ng SY; Chen DY
J Am Chem Soc; 2010 Jun; 132(23):8219-22. PubMed ID: 20496885
[TBL] [Abstract][Full Text] [Related]
8. Chlorinated englerins with selective inhibition of renal cancer cell growth.
Akee RK; Ransom T; Ratnayake R; McMahon JB; Beutler JA
J Nat Prod; 2012 Mar; 75(3):459-63. PubMed ID: 22280462
[TBL] [Abstract][Full Text] [Related]
9. Englerin a selectively induces necrosis in human renal cancer cells.
Sulzmaier FJ; Li Z; Nakashige ML; Fash DM; Chain WJ; Ramos JW
PLoS One; 2012; 7(10):e48032. PubMed ID: 23144724
[TBL] [Abstract][Full Text] [Related]
10. Chemical synthesis and biological evaluation of the englerin analogues.
Chan KP; Chen DY
ChemMedChem; 2011 Mar; 6(3):420-3. PubMed ID: 21360817
[No Abstract] [Full Text] [Related]
11. Englerin A Agonizes the TRPC4/C5 Cation Channels to Inhibit Tumor Cell Line Proliferation.
Carson C; Raman P; Tullai J; Xu L; Henault M; Thomas E; Yeola S; Lao J; McPate M; Verkuyl JM; Marsh G; Sarber J; Amaral A; Bailey S; Lubicka D; Pham H; Miranda N; Ding J; Tang HM; Ju H; Tranter P; Ji N; Krastel P; Jain RK; Schumacher AM; Loureiro JJ; George E; Berellini G; Ross NT; Bushell SM; Erdemli G; Solomon JM
PLoS One; 2015; 10(6):e0127498. PubMed ID: 26098886
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and in vivo anticancer activity of novel parthenolide and micheliolide derivatives as NF-κB and STAT3 inhibitors.
Zeng B; Cheng Y; Zheng K; Liu S; Shen L; Hu J; Li Y; Pan X
Bioorg Chem; 2021 Jun; 111():104973. PubMed ID: 34004586
[TBL] [Abstract][Full Text] [Related]
13. New sesquiterpene lactones, vernonilides A and B, from the seeds of Vernonia anthelmintica in Uyghur and their antiproliferative activities.
Ito T; Aimaiti S; Win NN; Kodama T; Morita H
Bioorg Med Chem Lett; 2016 Aug; 26(15):3608-11. PubMed ID: 27311895
[TBL] [Abstract][Full Text] [Related]
14. Total synthesis and biological evaluation of (-)-9-deoxy-englerin A.
Ushakov DB; Navickas V; Ströbele M; Maichle-Mössmer C; Sasse F; Maier ME
Org Lett; 2011 Apr; 13(8):2090-3. PubMed ID: 21413694
[TBL] [Abstract][Full Text] [Related]
15. Artematrovirenins A-P, guaiane-type sesquiterpenoids with cytotoxicities against two hepatoma cell lines from Artemisia atrovirens.
Su LH; Ma YB; Geng CA; Li TZ; Huang XY; Hu J; Xin Zhang ; Tang S; Shen C; Gao Z; Zhang XM; Chen JJ
Bioorg Chem; 2021 Sep; 114():105072. PubMed ID: 34144276
[TBL] [Abstract][Full Text] [Related]
16. Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
Yu M; Teo T; Yang Y; Li M; Long Y; Philip S; Noll B; Heinemann GK; Diab S; Eldi P; Mekonnen L; Anshabo AT; Rahaman MH; Milne R; Hayball JD; Wang S
Eur J Med Chem; 2021 Mar; 214():113248. PubMed ID: 33571827
[TBL] [Abstract][Full Text] [Related]
17. Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: design, synthesis, and structure-activity relationship study.
Jiang X; Zhou J; Ai J; Song Z; Peng X; Xing L; Xi Y; Guo J; Yao Q; Ding J; Geng M; Zhang A
Eur J Med Chem; 2015 Nov; 105():39-56. PubMed ID: 26476749
[TBL] [Abstract][Full Text] [Related]
18. Drug-like property optimization: Discovery of orally bioavailable quinazoline-based multi-targeted kinase inhibitors.
Lin SY; Chang CF; Coumar MS; Chen PY; Kuo FM; Chen CH; Li MC; Lin WH; Kuo PC; Wang SY; Li AS; Lin CY; Yang CM; Yeh TK; Song JS; Hsu JTA; Hsieh HP
Bioorg Chem; 2020 May; 98():103689. PubMed ID: 32171993
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation.
Yu M; Long Y; Yang Y; Li M; Teo T; Noll B; Philip S; Wang S
Eur J Med Chem; 2021 Jun; 218():113391. PubMed ID: 33823391
[TBL] [Abstract][Full Text] [Related]
20. Insight on a new indolinone derivative as an orally bioavailable lead compound against renal cell carcinoma.
Fouad MA; Zaki MY; Lotfy RA; Mahmoud WR
Bioorg Chem; 2021 Jul; 112():104985. PubMed ID: 34020239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
